Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BL-B01D1 + pembrolizumab with or without bevacizumab in recurrent or metastatic cervical cancer and endometrial cancer
CTR20252432Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan, pembrolizumab, bevacizumab in Cervical Cancer (CC), endometrial cancer (EC), sponsored by Biokin Pharmaceutical. Started Aug 2025; status: active.
02
Drugs
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20252432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252432.